Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131

May 14, 2020

Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update

May 7, 2020

Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update

Mar 9, 2020

Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study

Feb 19, 2020

Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

Jan 9, 2020

Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer

Jan 7, 2020

Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)

Jan 6, 2020

Cellectar Biosciences to Present at Biotech Showcase 2020

Dec 19, 2019

Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study

Dec 16, 2019

Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium

Dec 13, 2019